Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical CarcinomaLiem Phan, Mouhammed Amir Habra, Enrique Fuentes‐Mattei et al.|Cancer Research|2015Cited by 47
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III TrialKarim Fizazi, Stéphane Culine, Gwénaël Le Teuff et al.|Journal of Clinical Oncology|2024Cited by 18
High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell TumorsYago Nieto, Matthew T. Campbell, Roy B. Jones et al.|Clinical Cancer Research|2025Cited by 2
Supplementary Table Legend from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical CarcinomaLiem Phan, Mouhammed Amir Habra, Enrique Fuentes‐Mattei et al.|Unknown|2023Cited by 0
Supplementary Figures S1-S6 from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical CarcinomaLiem Phan, Mouhammed Amir Habra, Enrique Fuentes‐Mattei et al.|Unknown|2023Cited by 0